Renowned investor Jack Bogle, of the Vanguard Group explains to CNBC's Mandy Drury and the "Futures Now" traders why he has 70 percent of his money in bonds even though he likes stocks better. (1:39)
Gold gets a bounce off ECB comments and reaches a 3-week high. The precious metal's next move, with CNBC's Mandy Drury and the Futures Now Traders.
The dollar's pain is crude's gain. Oil gets bid off a weaker dollar. Crude's next move, with CNBC's Mandy Drury and the Futures Now Traders.
Although stocks have rallied of late, Jack Bogle, founder of the Vanguard Group, argues the move can't be attributed to investors leaving the bond market for equities, with CNBC's Mandy Drury and the Futures Now Traders.
After the Dow briefly hits a fresh high, professional traders comment on catalysts to equities, with CNBC's Mandy Drury and the Futures Now Traders.
Vanguard founder John Bogle looks at valuations, speculation and stocks vs. bonds. The biggest risk for investors, with CNBC's Mandy Drury and the Futures Now Traders, Jim Iourio at the CME and Anthony Grisanti at the Nymex.
The FMHR traders reveal their final trades.
The FMHR traders discuss how to play Google, Goldman Sachs, and other stocks requested on Twitter.
A U.S. energy revolution is underway as the country takes advantage of its abundant natural gas supplies. Here are some investment ideas.
The U.S. dollar is moving down today. How to play the currency, with Paul Richards of UBS.
Dissecting today's market action in the European markets, with CNBC's Simon Hobbs; and weighing in on activists role in the markets and whether stocks are still cheap is Aswath Damodaran, NYU Professor.
Valuations have put the stock market in a "sweet spot," but one factor could sour it, says NYU finance professor Aswath Damodaran.
VeriFone's CEO is stepping down, and the stock is going up, with the FMHR traders.
The Futures Now team discusses whether it is finally time to buy gold on the strength in the Japanese yen.
Investors in Allen Stanford's $7 billion Ponzi scheme, who have recovered nothing in the four years since it blew up, could finally get some money back under a $300 million multi-national settlement in the case.
The FMHR traders debate how to play Yum! Brands after the company's China sales fell less-than-expected; and Steve Grasso of Stuart Frankel offers his opinion on whether Merck has more upside ahead.
TheStreet.com reports its investor predictions for FDA drug approvals in 2013: Bad news for Arena Pharmaceuticals, Delcath Systems and Aveo Pharmaceuticals, but Sarepta Therapeutics and Ziopharm are among the winners.
Discussing which stocks will lead the rally's next leg, with Bob Doll, Nuveen Asset Management and the FMHR traders.
A look back at some of Gary Kaminsky's most memorable moments at CNBC, as he shares his final views on the future of interest rates and the biggest issues facing investors now.
In his daily CNBC.com-only video clip, Art Cashin of UBS talks with Bob Pisani about why it looks like the stock market rally will pause soon. (1:52)